Treatment of chronic prostatitis in individuals with diabetes: realities long phytotherapy

Authors

  • Ю. М. Гурженко ГУ «Институт урологии НАМН Украины», г. Киев
  • В. В. Спиридоненко ГУ «Институт урологии НАМН Украины», г. Киев

DOI:

https://doi.org/10.30841/2307-5090.3(58).2016.104480

Keywords:

chronic prostatitis, diabetes, lower urinary tract symptoms

Abstract

The objective: to evaluate the possibility of the long-term monotherapy with the Gentos Forte® in men with chronic prostatitis (CP) and diabetes mellitus (DM) with lower urinary tract symptoms (LTS).

Patients and methods. The advisory polyclinic SI «Institute of Urology of NAMS of Ukraine» was observed 78 men. The first group (n=42) consisted of persons with CP + signs on the background of LUTS verified diabetes type II (mean age 49,2±1,9 years) who received monotherapy Gentos Forte® (Bittner Pharma). A control group (group II) were patients with the same condition (mean age 45,2±1,0 years) treated with monotherapy with vitamin E 400 mg/once daily (n=31). History duration on diabetes disease averaged 5,6±0,7 years; Chronic prostatitis – an average of 13,5±0,7 years; for the duration of symptoms of LUTS – on average 2,0±0,4 years. The comparison group (Group III) were 5 healthy volunteers of age who are not receiving any treatment.

Results. As a result of treatment it was found that monotherapy with Gentos Forte® in patients of the I group is effective. The results of the study indicate that monotherapy with Gentos Forte® is a reliable alternative in individuals with a clinical Association CP, the DM and LUTS, and the effectiveness of the therapy directly depends on the process and duration of therapy.

Conclusions. 1. The clinical course of chronic prostatitis on a background of diabetes, is characterized by a persistent lower urinary tract symptoms, which requires long-term therapy, taking into account all the links of the pathogenesis of chronic inflammatory diseases.

2. Monotherapy Gentos Forte®, in terms of 120 days has helped to improve the patient’s condition, with decreasing LUTS manifestations 27.2%, improving the quality of life index of 37.2%, a decrease in prostate size by an average of 15.3%.

3. Monotherapy Gentos Forte® is highly effective and safe, improves the quality of life of men through the elimination of lower urinary tract symptoms, with the improvement of erectile function in 69.0% of patients in term of 120 days.

4. For 120 days use of the Gentos Forte®, 92.8% of men were satisfied with the results of treatment and want to continue it further.

Author Biographies

Ю. М. Гурженко, ГУ «Институт урологии НАМН Украины», г. Киев

Yu.M. Gurzhenko

В. В. Спиридоненко, ГУ «Институт урологии НАМН Украины», г. Киев

V.V. Spiridonenko

References

Waram J.H., Krolewski A.S. Epidemiology of diabetes mellitus // Joslin’s Diabetes mellitus. – Philadelphia: Lippincott Williams & Wilkins, 2006. – P. 115–144.

Основні показники діяльності ендокринол. служби України за 2000–2006 роки // Інститут ендокринол. та обміну речовин ім. В.П. Комісаренка. – К., –2000–2006. – 33 с.

Горпинченко И.И., Имшинецкая Л.П. Гормонотерапия половых расстройств у мужчин и другие методы медикаментозного лечения. – К.: Комполис, 2001. – 220 с.

Комаревцев В.Н., Спиридоненко В.В., Пепенин В.Р., Беличенко О.В., Пепенин С.В., Луцкий В.И. Фитотерапия и оптимизация показателей качества жизни и данных эякулята у лиц с хроническим простатитом // Здоровье мужчины. – 2001. – No 3 (38). – С. 34–39.

Горпинченко І.І., Гурженко Ю.М., Спиридоненко В.В. Сучасні дані про вплив хронічного запалення в патогенезі доброякісної гіперплазії передміхурової залози і раку передміхурової залози // Здоровье мужчины, 2014. – No 4. – С. 91–94.

Балаболкин М.И. Диабетология. – М.: Медицина; 2000. – С. 10–11.

Ефимов А.С. Патогенез и лечение хронических осложнений сахарного диабета // Ендокрінологія. – 2007. – No 12. – С. 73–74.

Дедов И.И., Курбатов Д.Г. и соавт. Урологические и андрологические заболевания при сахарном диабете // Урология. – 2009. – No 4. – С. 74–79.

Горпинченко И.И., Гурженко Ю.М., Спиридоненко В.В. Можливості впливу фітокорекції на пригнічення процесів доброякісної гіперплазії передміхурової залози в осіб із супутніми хронічними запальними захворюваннями передміхурової залози // Здоровье мужчины. – 2016. – No 1 (56). – С. 121–126.

Kessopoulou E., Russel J.M., Powers H.J. et al. A double blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated

male infertility //Fertil. Steril. 2007. – Vol. 64. – P. 825–831.

Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complement Ther Med. 2013 Jun;21(3):172–9.

Safarinejad M.R. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double rind, placebo-controlled, crossover study // J. Herb. Pharmacoter., 2005; V. 5(4). – P. 1–11 (lev. 1b).

Горпинченко И.И., Гурженко Ю.Н., Клименко П.М., Шуляк А.В., Спиридоненко В.В. Исследование Проспект 2 (ПРОСтамол: ПЕрспективы Комбинированной Терапии) при ДГПЖ // Здоровье мужчины. – 2012. – No 1. – С. 56–60.

De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. – V. 91. – P. 459–477.

Ficarra V, Rossanese M, Zazzara M et. al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy // Curr Urol Rep. 2014. Dec;15(12):P. 463.

Forray C., Bard J.A., Wetzel J.M. et al. The б1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human б1с subtype. Mol. Pharmacol. 1994; 45 (4):703–708.

Lowe F., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia// Curr. Opin. Urol. 2002; Vol. 12; P. 15.

Bostanci Y.; Kazzazi A.; Momtahen S., Laze J., Djavan В. Correlation between benign prostatic hyperplasia and inflammation // BENIGN PROSTATIC HYPERPLASIA. 2013 – Vol. 23 (1). – Р. 5–10.

Di Silverio F., Bosman C., Salvatori M. et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) // Eur. Urol. – 2005. – V. 47 – P. 72–79.

Berges R.R., Pientka L., Hufner K. et al. Male lower urinary tract symptoms and related health care seeking in Germany// Eur. Urology. 2001. – Vol. 39. – P. 682.

Vela-Navarrete R., Escribano-Burgos M., Farré A.L et al. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia // J Urol. – 2005 Feb; V. 173 (2). – P. 507–10.

Zhou T, Yang Y, Zhang H et al. Serenoa Repens Induces Growth Arrest, Apoptosis and Inactivation of STAT3 Signaling in Human Glioma Cells //Technol Cancer Res Treat. (2014 Jun V. 16. - P. 12-16.

Dennis L., Lynch C.F., Tornes J.C. Epidemiologic association between prostatitis and prostate cancer // Urology. – 2002. – V.60. – P. 78-83.

Abdelwahab S.I., Mohan S., Mohamed Elhassan M. et al. Antiapoptotic and Antioxidant Properties of Orthosiphon stamineus Benth (Cat’s Whiskers): Intervention in the Bcl-2-Mediated Apoptotic Pathway. Evid Based Complement Alternat Med. 2011; 2011:156765.

Mohamed E.A., Ahmad M., Ang L.F., Asmawi M.Z., Yam M.F. Evaluation of б-Glucosidase Inhibitory Effect of 50% Ethanolic Standardized Extract of Orthosiphon stamineus Benth in Normal and Streptozotocin-Induced Diabetic Rats. Evid Based Complement Alternat Med. 2015; 2015:754931.

Gao S., Chen W., Peng Z. et al. Urinary metabonomics elucidate the therapeutic mechanism of Orthosiphon stamineus in mouse crystal-induced kidney injury. J Ethnopharmacol. 2015 May 26; 166:323-32.

Al-Suede F.S., Khadeer Ahamed M.B., Abdul Majid A.S. et al. Optimization of Cat’s Whiskers Tea (Orthosiphon stamineus) Using Supercritical Carbon Dioxide and Selective Chemotherapeutic Potential against Prostate Cancer Cells. Evid Based Complement Alternat Med. 2014; 2014:396016.

Pagano E., Laudato M., Griffo M., Capasso R. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res. 2014 Jul;28(7):949-55.

Tomar P.P., Nikhil K., Singh A. et al. Characterization of anticancer, Dnase and antifungal activity of pumpkin 2S albumin. Biochem Biophys. Res. Commun. 2014 Jun 13;448(4):349-54.

Эффективность и безопасность препарата Простаплант®форте при LUTS, обусловленных доброкачественной гиперплазией предстательной железы (Обзор клинических исследований) // Здоровье мужчины, 2006. - No3. – С. 110 – 113.

Berges R.R., Pientka L., Hufner K. et al. Male lower urinary tract symptoms and related health care seeking in Germany. Eur. Urology. 2001; Vol. 39; P. 682.

Lowe F., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr. Opin. Urol. 2002; Vol. 12; P. 15.

Sokelend J., Schlafke S. Долгосрочные эффекты ПРО 160/120 (Простаплант®форте) у пациентов с симптоматической доброкачественной гиперплазией предстательной железы // Здоровье мужчины, 2007. - No4. – С. 68-69.

Неймарк С.А., Алиев Р.Т. Значение исследования энзимов спермальной плазмы в патогенезе относительного мужского бесплодия // Урология. – 2000. – No3. – С.34 – 37.

Кудрин А.В,, Скальный А.В., Жаворонков А.А. и др. Иммунофармакология микроэлементов. – М.: Из-во КМК. – 2000. – 537с.

Scheider T., Rubben H. Bennesseltrockenextrakt (Bazoton-uno) in der Langzeittherapie des benignen Prostatasyndroms (BPS). Ergebnisse einer ... //Urologe A. 2004. Mar; 43(3): P. 302-306.

Published

2016-10-26

Issue

Section

Sexology and andrology